COVID-19 Critical Intelligence Unit

Daily evidence digest

8 April 2022

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Fluvoxamine for outpatients, COVID-19 and stroke treatment response times, sotrovimab resistance in immunocompromised COVID-19 patients

Peer reviewed journals featured:

- · Systematic reviews on:
 - o Fluvoxamine for outpatient management of COVID-19 to prevent hospitalisation here
 - o Effects of COVID-19 on stroke treatment response times internationally here
- A narrative review on individualism and the fight against COVID-19 here
- Observational studies on:
 - A triage pathway to prioritise lower gastrointestinal endoscopy during COVID-19 here
 - Mental health service use, suicide behaviour, and emergency department visits among rural US veterans who received video-enabled tablets during COVID-19 here
 - o Sofosbuvir / velpatasvir for treating early mild to moderate COVID-19 here
 - o A Rhode Island statewide randomised controlled trial of vaccination nudges here
 - o Prolonged and extended impacts of SARS-CoV-2 on the olfactory neurocircuit here
 - Complementary and integrative medicine interventional study for frontline COVID-19 clinicians here
- A machine learning model for predicting SARS-COV-2 mortality risk and critical patients here
- A consensus statement on COVID-19 vaccination in Australian and New Zealand children undergoing treatment for cancer and non-malignant haematological conditions here
- Commentary on the need to retain reliable COVID-19 surveillance tools in the UK here

Letters and correspondence discussed:

- Pulse oximetry for monitoring patients with COVID-19 at home <u>here</u>
- Parsonage-Turner syndrome following COVID-19 vaccination <u>here</u>
- Vaccine uptake in the US after full FDA approval of Comirnaty (Pfizer) here
- Kinetics of humoral response to one, two, or three doses of COVID-19 vaccine in hematopoietic cell transplant recipients <u>here</u>
- Protection with a third dose of mRNA vaccine in frontline workers in the US here



Pre-peer review articles featured:

- High incidence of sotrovimab resistance and viral persistence after treatment of immunocompromised patients infected with Omicron here
- Omicron sublineage BA.2 replaces BA.1.1 from genomic surveillance in Japan here
- Classification of Omicron BA.1, BA.1.1, and BA.2 sublineages by TaqMan assay here
- Delta/ Omicron and Omicron/BA.2 co-infections occurring in immunocompromised hosts here

News and blogs

- What triggers severe COVID-19? here
- Why the WHO took two years to say COVID-19 is airborne here

<u>Click here</u> to subscribe to the daily evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on SARS-CoV-2 <u>vaccines</u>, and <u>variants</u> of concern, <u>post-acute sequelae of COVID-19 (PASC)</u>, <u>surgery and COVID-19</u>, <u>rapid testing</u> and <u>risk mitigation strategies</u>.



The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.